IJGC Podcast

HPV-independent Cervical Cancers with Andreina Fernandes

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Andreina Fernandes to discuss HPV-independent Cervical Cancers. Dr. Fernandes is a Molecular Biologist, Doctor of Science, and author of “Human papillomavirus-independent cervical cancer,” the Lead Article for the January 2022 issue of IJGC. Dr. Fernandes is a Researcher of the Molecular Genetics Laboratory at the Institute of Oncology and Hematology, and Professor of the Faculty of Dentistry, at Universidad Central de Venezuela in Caracas, Venezuela.
(https://ijgc.bmj.com/content/early/2021/12/08/ijgc-2021-003014)
Highlights:
-The percentage of HPV-independent tumors is very variable, around 5 and 10%.
-HPV-independent tumors are characterized by a differentiated molecular profile with lower proliferative activity, a p53 immunostaining, and alterations in PTEN, p53, KRAS, CTNNB1, ARID1A and ARID5B.
-Most HPV-independent tumors are adenocarcinomas, however, there have been reports of HPV-independent cases with squamous histology.
-HPV-independent tumors are associated with early lymph node involvement, accelerated tumor growth, distant metastasis, and a more aggressive biological behavior, related to a worse disease free survival and overall survival.
-The hit and run mechanism could explain the absence of the viral genome in the HPV-independent cervical cancer cases.
Andreina Fernandes (@AndreFernandes2)

Best of 2021: SENTOR Study: SLN in High-Risk Endometrial Cancer with Sarah Ferguson

In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Sarah Ferguson. Dr. Ferguson is a Professor in the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Toronto and a member of the Division of Gynecologic Oncology at University Health Network/Sinai Health Systems. She is the Director of Research for the Division of Gynecologic Oncology at Princess Margaret Cancer. Dr. Ferguson completed her residency in Obstetrics and Gynecology at University of Toronto and a fellowship at Memorial Sloan-Kettering Cancer Centre in Gynecologic Oncology. Current research program includes prospective surgical trials in cervical and endometrial cancer, evaluation of patient reported outcomes and molecular characterization of endometrial cancer.

Best of 2021: ESGO-ESTRO-ESP Endometrial Cancer Guidelines with Nicole Concin

In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Nicole Concin to discuss the ESGO-ESTRO-ESP Endometrial Cancer Guidelines (ijgc.bmj.com/content/early/2020…8/ijgc-2020-002230)

Best of 2021: ESGO Guidelines on Perioperative Management Ovarian Cancer with Christina Fotopoulou

In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Professor Christina Fotopoulou to discuss the ESGO Guidelines on Perioperative Management Ovarian Cancer. Professor Fotopoulou is the lead author of “European Society of Gynaecological Oncology guidelines for the peri-operative management of patients with ovarian cancer,” which is the Lead Article of IJGC’s September 2021 issue. Professor Fotopoulou works at the Department of Surgery and Cancer at Imperial College London, UK. She is an elected ESGO council member and Chair of the ESGO guidelines committee.

Reviewing the December Issue with Emma Allanson and Cecilia Darin

In this episode of the IJGC Podcast, Editorial Fellows Emma Allanson and Cecilia Darin discuss the contents of the December issue of IJGC in English.

Reviewing the December Issue with Natalia Rodriguez and Erick Estrada(Spanish version)

In this episode of the IJGC Podcast, Editorial Fellows Natalia Rodriguez and Erick Estrada discuss the contents of the December issue of IJGC in Spanish.

Combined metformin and progestin in endometrial cancer with Jennifer Chae-Kim

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Jennifer Chae-Kim. Dr. Chae-Kim is the author of Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis, which is the Lead Article of IJGC’s December 2021 issue. Dr. Chae-Kim is in her last year of OB/GYN residency at BSW-Temple, and will be pursuing her interests in fertility preservation and fellowship training in REI at the NIH next year.
https://ijgc.bmj.com/content/early/2021/11/15/ijgc-2021-002699
Jennifer Chae-Kim (@chae_md)
Highlights
1) Endometrial cancer and atypical endometrial hyperplasia are being diagnosed more frequently in reproductive-aged women, who may desire fertility-sparing therapy.
2) Women who received progestin and metformin therapy were found to have lower disease relapse rates than those who received progestin alone.
3) Combined therapy was not associated with significantly different rates of disease remission, pregnancy, live birth.
4) Further research is needed to determine the parameters of clinical application of metformin to progestin therapy.

Mentor’s Podcast: Andreas du Bois

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Professor Andreas du Bois. Professor du Bois completed his medical degree in 1987 at the University of Freiburg, Germany. He subsequently trained in general surgery at Krankenhaus Wolfach Personalwohnheim and gynaecology and obstetrics at the University of Freiburg, leading to his registration as Fellow for Gynaecology and Obstetrics in 1993.
In 1993, Prof. du Bois became a Consultant in the Department of Gynaecology and Obstetrics at St. Vincentius-Kliniken, Karlsruhe. He then served as Director of the Department of Gynaecology and Gynaecologic Oncology, Horst-Schmidt-Kliniken, Wiesbaden (19992010) before taking up his current roles as Director of the Departmenf of Gynaecology and Gynaecologic Oncology at Kliniken Essen-Mitte, and Associate Professor at Johannes Gutenberg University of Mainz, Germany.
Prof. du Bois has been the Principal Investigator of several pivotal and practice-changing international clinical trials in gynaecological oncology. He founded the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group in 1993 and co-founded the European Network of Gynaecological Oncological Trial groups (ENGOT) in 2007. He has previously been a member of the German Guideline Comittee for guidelines in breast, cervical, and ovarian cancer, Chairman of the German quality assurance programme for ovarian cancer (QS-OVAR), and member of the Gynecological Cancer InterGroup (GCIG) executive board and European Society of Gynaecological Oncology (ESGO) council. Prof. du Bois has been Chairman and a member of the Scientific Committee of the Ovarian Cancer Consensus Conference of the GCIG, and served as a member of the Scientific Committee of the 1st European Society of Medical Oncology (ESMO)-ESGO Ovarian Cancer Consensus Conference 2018. Prof. du Bois is a member of the American Society of Clinical Oncology (ASCO), ESGO, International Gynecologic Cancer Society (ISGC), German Cancer Society, and AGO. He has authored more than 500 publications with more than 33,500 citations, and has a Google Scholar h index of 86.
Prof. du Bois has received multiple honours and awards in recognition for his work, including the Arthur Walpole Award (German Cancer Society, 2006), Ernst Wertheim Award (Austrian Society of Gynecologic Oncology, 2006), MD Anderson Madrid Lifetime Award (2016), Wilhelm-Warner Prize for Cancer Research (2019), German Cancer Prize (Deutsche Krebsgesellschaft, 2020) and honorary membership of the German Society for Gynecology and Obstetrics (2020); 2021 he received the ESGO Lifetime Achievement Award (European Society of Gynaecological Oncology).

SLN in Endometrial Atypical Hyperplasia Jason Wright

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Jason Wright to discuss SLN in endometrial atypical hyperplasia. Dr. Wright is the Sol Goldman Associate Professor and Chief of the Division of Gynecologic Oncology at Columbia University.
Highlights:
-Performance of sentinel lymph node mapping is increasing in women undergoing hysterectomy for complex atypical endometrial hyperplasia.
-Sentinel lymph node mapping in women with atypical endometrial hyperplasia does not increase perioperative morbidity or mortality.
-The addition of sentinel lymph node mapping to surgery for endometrial hyperplasia is associated with increased hospital costs.

Reviewing the November Issue with Irina Tsibulak (Russian version)

In this episode of the IJGC Podcast, Editorial Fellow Irina Tsibulak discusses the contents of the November issue of IJGC in Russian.